journal article·2024-03

Biodegradable Osmium Nanoantidotes for Photothermal‐/Chemo‐ Combined Treatment and to Prevent Chemotherapy‐Induced Acute Kidney Injury

Qi Long, Fangling Liao, Huixi Yi, Mingcheng Wang, Jiani Zhuang, Yue Zheng, Weisheng Guo, Dong‐Yang Zhang

Advanced Healthcare Materials· Volume 13· Issue 7
Publisher page

Abstract

Abstract Acute kidney injury (AKI) is a common adverse event in chemotherapy patients. AKI is accompanied by the generation of reactive oxygen species (ROS) and inflammation. Therefore, the management of ROS and inflammation is a potential strategy for AKI mitigation. Herein, polyethylene glycol‐coated osmium nanozyme‐based antidotes (Os) are developed for imaging‐guided photothermal therapy (PTT) in combination with cisplatin (Pt); while, avoiding AKI induced by high‐dose Pt. Os nanoantidotes can enhance the efficiency of tumor treatment during combined PTT and chemotherapy and inhibit tumor metastasis by improving the hypoxic and inflammatory tumor microenvironment. Os nanoantidotes preferentially accumulate in the kidney because of their 2‐nm size distribution; and then, regulate inflammation by scavenging ROS and generating oxygen to alleviate Pt‐induced AKI. Os nanoantidotes can be cleared from the kidneys by urine excretion but can be degraded under hydrogen peroxide stimulation, reducing the bio‐retention of these compounds. By integrating PTT with inflammatory regulation, Os nanoantidotes have the potential to reduce the side effects of chemotherapy, offering an alternative route for the clinical management of cancer patients with chemotherapy‐induced AKI.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology the NMPA and State Key Laboratory of Respiratory Disease the Fifth Affiliated Hospital and School of Pharmaceutical Sciences Guangzhou Medical University Guangzhou 511436 China

Breast Tumor Center Sun Yat‐Sen Memorial Hospital Sun Yat‐Sen University Guangzhou 510275 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (62)

Show source-provided references
1. 10.1038/s41551-020-0582-110.1038/s41551-020-0582-1 ↗
2. 10.1056/NEJMra121424310.1056/NEJMra1214243 ↗
3. 10.1016/S0140-6736(11)61454-210.1016/S0140-6736(11)61454-2 ↗
4. 10.1038/nrneph.2013.14610.1038/nrneph.2013.146 ↗
5. 10.1016/j.ccr.2021.21421010.1016/j.ccr.2021.214210 ↗
6. 10.1016/j.cej.2019.12356310.1016/j.cej.2019.123563 ↗
7. 10.1038/nrneph.2009.15510.1038/nrneph.2009.155 ↗
8. 10.1038/nrneph.2014.18010.1038/nrneph.2014.180 ↗
9. 10.3390/nu907071810.3390/nu9070718 ↗
10. 10.1002/anie.20191013710.1002/anie.201910137 ↗
11. 10.1056/NEJMoa080263910.1056/NEJMoa0802639 ↗
12. 10.1038/ki.2014.32810.1038/ki.2014.328 ↗
13. 10.1016/j.pharmthera.2013.09.00610.1016/j.pharmthera.2013.09.006 ↗
14. 10.1007/BF0068532610.1007/BF00685326 ↗
15. 10.1016/S0959-8049(96)00328-010.1016/S0959-8049(96)00328-0 ↗
16. 10.1111/j.1523-1755.2004.00516.x10.1111/j.1523-1755.2004.00516.x ↗
17. 10.1016/j.biomaterials.2021.12070610.1016/j.biomaterials.2021.120706 ↗
18. 10.1002/adma.20230128310.1002/adma.202301283 ↗
19. 10.1002/smll.20200511310.1002/smll.202005113 ↗
20. 10.1038/s41467-020-16544-710.1038/s41467-020-16544-7 ↗
21. 10.1021/acs.accounts.0c0032310.1021/acs.accounts.0c00323 ↗
22. 10.1126/sciadv.abb742210.1126/sciadv.abb7422 ↗
23. 10.1038/s41467-021-21714-210.1038/s41467-021-21714-2 ↗
24. 10.1021/acscentsci.0c0076310.1021/acscentsci.0c00763 ↗
25. 10.1039/C8CS00718G10.1039/C8CS00718G ↗
26. 10.1002/anie.20181399410.1002/anie.201813994 ↗
27. 10.1002/anie.20191614210.1002/anie.201916142 ↗
28. 10.1002/advs.20190199210.1002/advs.201901992 ↗
29. 10.1016/j.nantod.2020.10093510.1016/j.nantod.2020.100935 ↗
30. 10.1039/D0CS00461H10.1039/D0CS00461H ↗
31. 10.1016/j.biocel.2021.10614110.1016/j.biocel.2021.106141 ↗
32. 10.1016/j.nantod.2020.10092510.1016/j.nantod.2020.100925 ↗
33. 10.1021/acsnano.8b0878510.1021/acsnano.8b08785 ↗
34. 10.1002/anie.20170964810.1002/anie.201709648 ↗
35. 10.1126/science.aaf440510.1126/science.aaf4405 ↗
36. 10.1016/S0140-6736(00)04046-010.1016/S0140-6736(00)04046-0 ↗
37. Peng H. · Exploration · 2023 · 3 · 202
38. 10.1016/j.cej.2022.13571110.1016/j.cej.2022.135711 ↗
39. 10.1021/acsnano.6b0665110.1021/acsnano.6b06651 ↗
40. 10.1002/adma.20200114610.1002/adma.202001146 ↗
41. 10.1038/s41467-019-12313-310.1038/s41467-019-12313-3 ↗
42. 10.1039/C8CS00618K10.1039/C8CS00618K ↗
43. 10.1021/jacs.1c0975310.1021/jacs.1c09753 ↗
44. 10.1002/anie.20210192410.1002/anie.202101924 ↗
45. 10.1038/s41565-019-0527-610.1038/s41565-019-0527-6 ↗
46. 10.1002/anie.20171058410.1002/anie.201710584 ↗
47. 10.1002/adma.20170436710.1002/adma.201704367 ↗
48. 10.1038/nnano.2006.17010.1038/nnano.2006.170 ↗
49. 10.1021/acsami.1c1190710.1021/acsami.1c11907 ↗
50. 10.1039/D0TA09247A10.1039/D0TA09247A ↗
51. 10.1149/1.297519110.1149/1.2975191 ↗
52. 10.1021/acsami.1c1420110.1021/acsami.1c14201 ↗
53. 10.1016/j.bioactmat.2022.08.02210.1016/j.bioactmat.2022.08.022 ↗
54. 10.1038/s41551-018-0317-810.1038/s41551-018-0317-8 ↗
55. 10.1038/s41467-018-07890-810.1038/s41467-018-07890-8 ↗
56. 10.1038/nbt.162310.1038/nbt.1623 ↗
57. 10.1038/s41563-019-0378-410.1038/s41563-019-0378-4 ↗
58. 10.1021/acsnano.1c0823710.1021/acsnano.1c08237 ↗
59. 10.1021/ja508641z10.1021/ja508641z ↗
60. 10.1002/advs.20180058110.1002/advs.201800581 ↗
61. 10.1016/j.biomaterials.2021.12097910.1016/j.biomaterials.2021.120979 ↗
62. 10.1038/ncomms900310.1038/ncomms9003 ↗